Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: Meta-analytical estimation and implications for therapeutic strategies

Fotios Loupakis, Chiara Cremolini, Lisa Salvatore, Marta Schirripa, Sara Lonardi, Vanja Vaccaro, Federica Cuppone, Diana Giannarelli, Vittorina Zagonel, Francesco Cognetti, Giampaolo Tortora, Alfredo Falcone, Emilio Bria

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Antiepidermal growth factor receptor (anti-EGFR) monoclonal antibodies (MoAbs) are indicated for the treatment of metastatic colorectal cancer patients, but some scientific issues concerning their efficacy are currently unsolved. METHODS: A literature-based meta-analysis was conducted. Hazard ratios (HRs) were extracted from randomized trials for progression-free survival (PFS) and overall survival (OS); the event-based risk ratio was derived for response. Sensitivity analyses to look for interactions according to KRAS status and chemotherapy association regimens were performed. RESULTS: Eight trials (6609 patients) were identified. A significant interaction according to KRAS status was found for PFS (wild type vs mutant, P =.001) and response rate (wild type vs mutant, P

Original languageEnglish
Pages (from-to)1523-1532
Number of pages10
JournalCancer
Volume118
Issue number6
DOIs
Publication statusPublished - Mar 15 2012

Keywords

  • cetuximab
  • chemotherapy
  • colorectal cancer
  • meta-analysis
  • panitumumab

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: Meta-analytical estimation and implications for therapeutic strategies'. Together they form a unique fingerprint.

  • Cite this